Studies have indicated that BRD7 often acts as a tumor suppressor [40], whereas BRD9 is a pro-oncogenic protein [44], the mechanism of which is potentially linked with the STAT5 signaling pathway and the expression of MYC in hematological tumors [44, 45]. The gene discussed is MYC; the disease is neoplasm.